Filana Therapeutics (FLNA) Income from Continuing Operations (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Income from Continuing Operations of 9557000.0 for Q2 2026, up 79.02% year-over-year from 5338577.07 in Q2 2025, and up 15.98% quarter-over-quarter from 11374000.0 in Q1 2026.
Filana Therapeutics (FLNA) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Filana Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 9557000.0 for Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 79.02% year-over-year to 9557000.0; the TTM figure through Jun 2026 stood at 46705000.0 (up 64.3% YoY), while the FY2025 annual figure was 207286000.0, up 12.95% from the prior year.
- Income from Continuing Operations for Q2 2026 stood at 9557000.0, up from 11374000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 9557000.0 in Q2 2026, with the low at 61617000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 21979500.0 (2022), against an average of 24506833.33.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations slumped 371.72% in 2022, then surged 79.02% in 2026.
- Filana Therapeutics' Income from Continuing Operations stood at 19813000.0 in 2022, then retreated by 16.5% to 23082000.0 in 2023, then fell by 28.39% to 29636000.0 in 2024, then jumped by 53.83% to 13684000.0 in 2025, then surged by 30.16% to 9557000.0 in 2026.
- Business Quant data shows FLNA's Income from Continuing Operations at 9557000.0 in Q2 2026, 11374000.0 in Q1 2026, and 13684000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Filana Therapeutics | 46.00 Mn | 46.00 Mn | - | -8.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.56 Mn |
| Mar 31, 2026 | -11.37 Mn |
| Dec 31, 2025 | -13.68 Mn |
| Sep 30, 2025 | -12.09 Mn |
| Jun 30, 2025 | -45.55 Mn |
| Mar 31, 2025 | -24.80 Mn |
| Dec 31, 2024 | -29.64 Mn |
| Sep 30, 2024 | -30.85 Mn |
| Jun 30, 2024 | -61.62 Mn |
| Mar 31, 2024 | -20.18 Mn |
| Dec 31, 2023 | -23.08 Mn |
| Sep 30, 2023 | -28.24 Mn |
| Jun 30, 2023 | -26.94 Mn |
| Mar 31, 2023 | -24.83 Mn |
| Dec 31, 2022 | -19.81 Mn |
| Sep 30, 2022 | -20.88 Mn |
| Jun 30, 2022 | -19.91 Mn |
| Mar 31, 2022 | -18.10 Mn |
| Dec 31, 2021 | -14.47 Mn |
| Sep 30, 2021 | -9.78 Mn |